Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?

Current pharmaceutical design - 1 Jan 2012

Laine Marc, Camoin-Jau Laurence, Bessereau Jacques, Sébastien Armero, Paganelli Franck, Bonello Laurent

Abstract excerpt

P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization. Multiple lines of evidence suggest that the level of on-treatment platelet reactivity inhibition with P2Y12 ADP receptor antagonists correlates with thrombotic recurrences. Recent studies observed a relationship...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coronary Thrombosis
Share to Percutaneous Coronary Intervention

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Platelet Activation

Share to Platelet Function Tests

Share to Prasugrel Hydrochloride

Share to Receptors, Purinergic P2Y12

Share to Thiophenes

Share to Ticagrelor

Source

Identifiers

PMID: 22724420
DOI: 10.2174/138161212803251934

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?PMID 22724420Read ↗

Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.Semantic proximity Read ↗

High platelet reactivity and clinical outcome - fact and fiction.Semantic proximity Read ↗

Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey.Semantic proximity Read ↗

Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance.Semantic proximity Read ↗

Recent developments in the use of antiplatelet agents to prevent cardiovascular events.Semantic proximity Read ↗

Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.Semantic proximity Read ↗

Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. A systematic review.Semantic proximity Read ↗

Response variability to P2Y12 receptor inhibitors: expectations and reality.Semantic proximity Read ↗

Whole blood dynamic platelet aggregation counting and 1-year clinical outcomes in patients with coronary heart diseases treated with clopidogrel.Semantic proximity Read ↗

Options to overcome clopidogrel response variability.Semantic proximity Read ↗

P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists.Semantic proximity Read ↗

Optimisation of anti-platelet therapy in acute coronary syndromesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.